# GSK plc: overview GSK · NYSE · CIK 1131399 · [Healthcare](/sectors/healthcare.md) Pages: [Overview](/companies/gsk.md) · [Financials](/companies/gsk/financials.md) · [Filings](/companies/gsk/filings.md) · [Insiders](/companies/gsk/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $bn | [24.7](/filings/0001131399-24-000007.md) | [29.3](/filings/0001131399-24-000007.md) | [30.3](/filings/0001131399-25-000007.md) | [31.4](/filings/0001131399-26-000004.md) | [32.7](/filings/0001131399-26-000004.md) | | Gross margin | % | [66.9%](/filings/0001131399-24-000007.md) | [67.4%](/filings/0001131399-25-000007.md) | [71.8%](/filings/0001131399-26-000004.md) | [71.2%](/filings/0001131399-26-000004.md) | [72.4%](/filings/0001131399-26-000004.md) | | Operating margin | % | [17.6%](/filings/0001131399-24-000007.md) | [21.9%](/filings/0001131399-25-000007.md) | [22.2%](/filings/0001131399-26-000004.md) | [12.8%](/filings/0001131399-26-000004.md) | [24.3%](/filings/0001131399-26-000004.md) | | Net margin | % | [17.8%](/filings/0001131399-24-000007.md) | [51.0%](/filings/0001131399-25-000007.md) | [16.2%](/filings/0001131399-26-000004.md) | [8.2%](/filings/0001131399-26-000004.md) | [17.5%](/filings/0001131399-26-000004.md) | | Diluted EPS | $ per share | [1.08](/filings/0001131399-24-000007.md) | [3.66](/filings/0001131399-25-000007.md) | [1.20](/filings/0001131399-26-000004.md) | [0.62](/filings/0001131399-26-000004.md) | [1.39](/filings/0001131399-26-000004.md) | | Free cash flow | $bn | [7.0](/filings/0001131399-24-000007.md) | [6.3](/filings/0001131399-25-000007.md) | [5.5](/filings/0001131399-26-000004.md) | [5.2](/filings/0001131399-26-000004.md) | [6.4](/filings/0001131399-26-000004.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/gsk/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $3.41bn | 64,961,641 | | Reduced −2,700,005 | | [Dodge & Cox](/funds/200217.md) | 2026-06-30 | $2.53bn | 48,197,514 | | Reduced −10,465,460 | | [Fisher Asset Management, LLC](/funds/850529.md) | 2026-06-30 | $1.87bn | 35,722,792 | | Added +1,200,429 | | [PRIMECAP MANAGEMENT CO/CA/](/funds/763212.md) | 2026-06-30 | $1.32bn | 25,182,068 | | Reduced −22,470 | | [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $597.4m | 11,396,249 | | Reduced −321,364 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $401.4m | 7,657,562 | | Reduced −3,373,089 | | [ROYAL BANK OF CANADA](/funds/1000275.md) | 2026-06-30 | $397.8m | 7,588,928 | | Added +82,142 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $334.0m | 6,371,442 | | Reduced −3,217,672 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $315.1m | 5,959,115 | | Reduced −39,371 | | [Mondrian Investment Partners LTD](/funds/1317724.md) | 2026-06-30 | $257.4m | 4,910,830 | | Reduced −76,563 | ## Recent filings [All 4,469 filings](/companies/gsk/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 12:16 ET | [6-K](/filings/0001654954-26-009141.md) | Report of a foreign private issuer, period 2026-10-26 | 0001654954-26-009141 | | 2026-10-26 | 12:05 ET | [6-K](/filings/0001654954-26-009139.md) | Report of a foreign private issuer, period 2026-10-26 | 0001654954-26-009139 | | 2026-10-26 | 06:51 ET | [6-K](/filings/0001654954-26-009130.md) | Report of a foreign private issuer, period 2026-10-26 | 0001654954-26-009130 | | 2026-10-26 | 06:32 ET | [6-K](/filings/0001654954-26-009127.md) | Report of a foreign private issuer, period 2026-10-26 | 0001654954-26-009127 | | 2026-10-21 | 06:14 ET | [6-K](/filings/0001654954-26-009062.md) | Report of a foreign private issuer, period 2026-10-21 | 0001654954-26-009062 | | 2026-10-19 | 13:06 ET | [6-K](/filings/0001654954-26-009036.md) | Report of a foreign private issuer, period 2026-10-19 | 0001654954-26-009036 | | 2026-10-19 | 07:25 ET | [6-K](/filings/0001654954-26-009023.md) | Report of a foreign private issuer, period 2026-10-19 | 0001654954-26-009023 | | 2026-10-15 | 10:47 ET | [6-K](/filings/0001654954-26-008959.md) | Report of a foreign private issuer, period 2026-10-15 | 0001654954-26-008959 | | 2026-10-14 | 11:42 ET | [6-K](/filings/0001654954-26-008950.md) | Report of a foreign private issuer, period 2026-10-14 | 0001654954-26-008950 | | 2026-10-13 | 11:12 ET | [6-K](/filings/0001654954-26-008921.md) | Report of a foreign private issuer, period 2026-10-13 | 0001654954-26-008921 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001131399-26-000004.md), filed Mar 6, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1131399 - Tickers: GSK, GLAXF - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: X0 - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 12:18 ET. No prices; not investment advice.